Israel’s Atox Bio announced the success of Phase Iia clinical trials of its AB103 treatment of Necrotizing Soft Tissue Infections (NSTI). NSTIs are life-threatening bacterial infections with significant morbidity and high mortality rate.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000799752&fid=1725